A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing
About this study
The study is planned to observe and document the therapeutic decision-making process, treatment protocols, and clinical outcomes in patients with luminal breast cancer, whether they have undergone EndoPredict® testing or not
- Condition
- Breast Cancer, Breast Adenocarcinoma
- Sponsor
- National and Kapodistrian University of Athens
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Study condition: Breast Cancer, Breast Adenocarcinoma
- Age ≥ 18 years old.
- Histological diagnosis of invasive breast cancer.
- T1-T3 tumor size.
- 0-3 positive axillary lymph nodes.
- Documented ER-positive tumor by immunohistochemistry (≥1% or Allred Score: ≥3/8 or H-score: ≥50/ 300)
- Documented HER2-negative tumor by immunohistochemistry and/or in situ hybridization
- Subject with signed and dated informed consent form.
Exclusion 3
- History of another primary malignancy within the last 5 years, except for resected non-melanoma skin cancer.
- Pre-operative chemotherapy administered.
- Subject without signed and dated informed consent form.
Where
13 sites, 13 recruiting
"Elena Venizelou" General Hospital, Department of Surgery
Athens, Greece
"Prolipsis" Center, Breast Unit
Athens, Greece
Henry Dunant Hospital Center, 3rd Breast Surgical Department
Athens, Greece
Laiko Hospital, National and Kapodistrian University of Athens, Medical School
Athens, Greece
Mediterraneo Hospital, Breast Clinic
Athens, Greece
Metropolitan General Hospital, 3rd Breast Clinic
Cholargós, Greece
and 7 more sites on ClinicalTrials.gov
Contact
-
Michalis Kontos
+30 2132060800 michalis_kontos@yahoo.com
Potential match only. Final eligibility is determined by the study team.